Elephants never forget, the saying goes. Can they teach us about Alzheimer's disease? (Fortune)

Whether omega-3 fatty acid supplementation is beneficial, neutral, or harmful for seizure control and SUDEP (sudden and unexpected death in epilepsy) is unclear, neurologists argue. (JAMA Neurology)

Glaucoma, age-related macular degeneration, and diabetic retinopathy may be tied to increased Alzheimer's disease risk, a study of 3,800 patients reported. (Alzheimer's and Dementia)

The FDA approved the first RNA interference drug, patisiran (Onpattro), to treat polyneuropathy associated with hereditary transthyretin amyloidosis.

After scrapping its in-house neuroscience work earlier this year, Pfizer is investing in discovery-stage neuro startups. (Endpoints News)

A daily pack of cigarettes during natalizumab treatment increased the relapse rate of relapsing-remitting multiple sclerosis by 38%, Danish researchers reported. (Multiple Sclerosis Journal)

A therapy robot with a friendly face may be able to teach social skills to children with autism. (IEEE Spectrum)

Innate Immunotherapeutics, an Australian biotech company that was testing the multiple sclerosis drug MIS416, is at the center of the Rep. Christopher Collins (R-N.Y.) insider trading story. (New York Times)

More than half the pregnancies in women with epilepsy were unintended even though planning for pregnancy is of "utmost importance" for these patients, researchers said. (Neurology)

PARP (poly-ADP ribose polymerase) inhibitors, a targeted therapy for certain types of cancer, show promise in treating amyotrophic lateral sclerosis and frontotemporal degeneration, Penn researchers reported. (Fierce Biotech)